2023
DOI: 10.1016/j.omtm.2023.01.006
|View full text |Cite
|
Sign up to set email alerts
|

Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
3
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 14 publications
(4 citation statements)
references
References 55 publications
0
3
0
Order By: Relevance
“…The choice of AAV serotype as a tool for gene delivery or gene editing depends on the tropism for desired target tissues as well as the ability to generate sufficiently high-quality titers. AAV6-based vectors became commonly used for targeting lymphoid cells [48][49][50], myeloid cells [42,[50][51][52], hematopoietic stem cells [53,54], muscular cells [55][56][57], cardiomyocytes [58][59][60], pulmonary cells [44,61] and others.…”
Section: Discussionmentioning
confidence: 99%
“…The choice of AAV serotype as a tool for gene delivery or gene editing depends on the tropism for desired target tissues as well as the ability to generate sufficiently high-quality titers. AAV6-based vectors became commonly used for targeting lymphoid cells [48][49][50], myeloid cells [42,[50][51][52], hematopoietic stem cells [53,54], muscular cells [55][56][57], cardiomyocytes [58][59][60], pulmonary cells [44,61] and others.…”
Section: Discussionmentioning
confidence: 99%
“…Both AAV9 and AAV-DJ vectors were packaged in a single-strain expression cassette with chicken β-actin (CBA) promoter-driven fusion of firefly luciferase (Luc), and yellow fluorescent protein (YFP) (24,25). Recombinant AAV vectors were produced using the triple transfection method and purified as described previously (26,27). Briefly, HEK293 cells were co-transfected with three plasmids encoding 1) Rep/Cap, 2) ITRs-CBA- fLuc-YFP , and 3) Ad helper genes using polyethyleneimine (#23966-1, Polysciences, USA).…”
Section: Methodsmentioning
confidence: 99%
“…Subsequently, the viral DNA was cleaned using DNA Clean & Concentrator TM 25 (#11-305C, Genesee Scientific, USA). Vector titers were quantified by qPCR with a TBGreen ® Advantage (#S4748, Takara Bio, USA), using the following primer pair specific to the CBA promoter region within the viral cassette: forward primer 5’-TCCCATAGTAACGCCAATAGG -3’ and reverse primer 5’- CTTGGCATATGATACACTTGATG -3’(26,27).…”
Section: Methodsmentioning
confidence: 99%
“…[97][98][99] Viral gene delivery vectors have many advantages and have been extensively explored for cancer gene delivery, but their immunogenicity and high toxicity limit their clinical application. [100,101] Besides, viral vectors generally face problems of large-scale vector manufacturing and cost, for example, Glybera is priced at 1 million euros per patient. [102] Compared with viral vectors, nonviral vectors (e.g., lipids, polymers, dendrimer, polypeptide, and inorganic structures, etc.)…”
Section: Gene Therapymentioning
confidence: 99%